PDCD1 and cancer: Therapeutic monoclonal antibodies (mAbs) targeting the immune checkpoints cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) have revolutionized the treatment of various cancers.